V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220019813 | 220018091 | null | 59 | Not known (9) | 2017-12-11 | 2018-01-05 | Arsenic trioxide | null | null | 220033933 | LENALIDOMIDE |
| 220019814 | 220009004 | 1.7 | 93.6 | Disease modification (D) | 2015-02-22 | 2015-05-16 | AML Relapsed FLA | 2 | N | 220033943 | MACE |
| 220019815 | 220009005 | 1.4 | 55 | Not known (9) | null | 2014-05-10 | TRASTUZUMAB | Y | N | 220033951 | TRASTUZUMAB |
| 220019816 | 220009008 | null | null | null | 2014-06-05 | 2014-06-18 | LENALIDOMIDE | N | N | 220033957 | TIP |
| 220019817 | 220014813 | null | null | Disease modification (D) | null | 2016-09-25 | Cytarabine+Methotrexate Intrathecal | Y | N | 220033965 | FLUDARABINE |
| 220019818 | 220009017 | -1 | null | null | 2016-06-10 | 2016-08-02 | EOX | null | N | 220033984 | VINCRISTINE |
| 220019819 | 220009020 | 1.64 | 47.4 | Curative (C) | 2014-03-04 | 2014-05-20 | FEC 100 | N | N | 220033988 | DACARBAZINE |
| 220019820 | 220018094 | 1.76 | 55.4 | null | 2018-04-12 | 2018-07-11 | DABRAFENIB | N | N | 220033997 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220019821 | 220009028 | 1.73 | 46.7 | Curative (C) | 2017-07-31 | 2017-07-31 | Trastuzumab Subcutaneous | N | N | 220034002 | WT1 TRIAL |
| 220019822 | 220009030 | 1.8 | 62.2 | Curative (C) | 2017-03-23 | 2017-03-25 | PEMBROLIZUMAB | null | N | 220034012 | EVEROLIMUS |
| 220019823 | 220009032 | 1.52 | 71 | Disease modification (D) | 2015-10-30 | 2016-11-29 | CETUXIMAB | N | N | 220034022 | ARSENIC TRIOXIDE + ATRA |
| 220019824 | 220018097 | 1.72 | null | Palliative (P) | 2016-07-02 | 2016-07-10 | CAV | N | N | 220034035 | CAPECITABINE + OXALIPLATIN |
| 220019825 | 220009038 | 1.87 | 85.5 | Curative (C) | 2018-11-24 | 2018-11-24 | Carboplatin + Irinotecan | 2 | N | 220034038 | MIDAC |
| 220019826 | 220009041 | 1.54 | 58 | Curative (C) | 2015-05-06 | 2015-05-20 | VINORELBINE | N | N | 220034055 | ALEMTUZUMAB + FLUDARABINE |
| 220019827 | 220009046 | 1.53 | 66.8 | Curative (C) | 2014-10-14 | 2014-12-25 | CAPECITABINE + OXALIPLATIN | 02 | N | 220034070 | FLUOROURACIL |
| 220019828 | 220009048 | 1.65 | 71 | Curative (C) | 2014-12-26 | 2014-12-26 | MACE | 01 | N | 220034076 | BUSULPHAN + CYCLO |
| 220019829 | 220009048 | 1.72 | 71.8 | Curative (C) | 2015-05-20 | 2015-05-20 | Sorafenib | null | N | 220034076 | LENALIDOMIDE |
| 220019830 | 220009052 | 1.65 | null | Curative (C) | 2014-04-08 | 2014-04-12 | PEMBROLIZUMAB | N | N | 220034081 | CYTARABINE IT + METHOTREXATE |
| 220019831 | 220009061 | 1.8 | null | Curative (C) | 2016-11-23 | 2016-11-24 | Spanish Maintenance (Months 1-3) | null | null | 220034115 | VINCRISTINE |
| 220019832 | 220009066 | 1.52 | 54.6 | Disease modification (D) | 2014-05-16 | 2014-05-20 | MA (Cytarabine 3g/m2) | 02 | Y | 220034117 | TRASTUZUMAB |
| 220019833 | 220009070 | 1.64 | 78.4 | Curative (C) | 2018-05-29 | 2018-06-28 | VINORELBINE | N | N | 220034127 | FLA |
| 220019834 | 220009073 | 1.73 | 78.3 | Curative (C) | 2018-02-14 | 2018-02-14 | Cetuximab + FOLFIRI cycle1 | N | Y | 220034132 | ARSENIC TRIOXIDE + ATRA |
| 220019835 | 220009080 | 1.67 | 61 | Not known (9) | 2016-06-10 | 2017-03-08 | MELPHALAN | Y | N | 220034156 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220019836 | 220009081 | null | 60.7 | Palliative (P) | 2018-09-12 | 2018-09-12 | Cytarabine+Methotrexate Intrathecal | N | N | 220034164 | FLUDARABINE |
| 220019837 | 220014845 | 1.51 | 76 | Palliative (P) | 2016-07-11 | 2016-09-28 | GDCVP | 02 | null | 220034194 | CETUXIMAB |
| 220019838 | 220009087 | null | null | Curative (C) | 2015-10-19 | 2015-11-02 | EOX | null | N | 220034195 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220019839 | 220009089 | 1.75 | 59 | Curative (C) | 2015-06-07 | 2015-07-08 | MITOXANTRONE + TRETINOIN | 02 | N | 220034214 | ALEMTUZUMAB + FLUDARABINE |
| 220019840 | 220009091 | null | 80 | Curative (C) | 2016-10-03 | 2017-02-02 | Ipilimumab | N | null | 220034218 | ALL INTENSIFICATION |
| 220019842 | 220014856 | 1.64 | 88.5 | Curative (C) | 2017-04-11 | 2017-08-05 | CAMELLIA Trial | N | N | 220034274 | CISPLATIN + ETOPOSIDE |
| 220019843 | 220019941 | 1.57 | 64.6 | Curative (C) | 2016-04-17 | 2016-05-15 | Capecitabine | 02 | N | 220034302 | MACE |
| 220019844 | 220014861 | 0 | 87 | null | 2016-05-19 | 2016-05-19 | ATG + Busulfan + Fludarabine + Thiotepa | 01 | N | 220034322 | SORAFENIB |
| 220019845 | 220009114 | 1.52 | 0 | Curative (C) | 2014-04-06 | 2014-04-06 | Alemtuzumab+Busulfan+CyclophosphMUD | 02 | N | 220034334 | RAVVA TRIAL |
| 220019846 | 220018115 | 1.76 | 74.4 | Palliative (P) | 2013-01-09 | 2013-07-30 | ATG + BUSULFAN + CYCLOPHOSPHAMIDE | 02 | N | 220034340 | BUSULPHAN + CYCLO |
| 220019847 | 220009118 | 1.77 | 76 | Curative (C) | 2014-02-23 | 2014-03-22 | MITOMYCIN | 02 | N | 220034346 | CETUXIMAB + IRINOTECAN + MDG |
| 220019848 | 220018117 | 1.7 | null | Neo-adjuvant (N) | 2014-01-30 | 2014-02-06 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN | N | null | 220034352 | EOX |
| 220019849 | 220009124 | 1.63 | 107.8 | Curative (C) | 2015-09-20 | 2015-10-07 | CYTARABINE + FLUDARABINE | 02 | N | 220034356 | FLUOROURACIL |
| 220019850 | 220009126 | null | 85 | Not known (9) | 2017-12-03 | 2017-12-04 | ALEMTUZUMAB + FLUDARABINE | null | null | 220034364 | MYELOMA XI TRIAL |
| 220019851 | 220009133 | 1.8 | 21.4 | null | 2015-04-16 | 2017-03-10 | Cetuximab 14 day | N | N | 220034423 | CISPLATIN |
| 220019852 | 220019943 | 0 | 76.6 | Curative (C) | null | 2018-07-10 | Cladribine (subcut) 5 days | 02 | N | 220034424 | CAPECITABINE |
| 220019853 | 220009140 | 1.91 | 0 | Disease modification (D) | 2014-04-18 | 2015-09-11 | MITOXANTRONE + TRETINOIN | 2 | N | 220034425 | GDCVP |
| 220019854 | 220009141 | 1.67 | null | Curative (C) | 2016-02-22 | 2017-11-29 | MA (Cytarabine 3g/m2) | N | N | 220034425 | CETUXIMAB + CISPLATIN + FU |
| 220019855 | 220009147 | 1.76 | 86.9 | Curative (C) | 2017-05-18 | 2017-05-18 | Busulfan + Cyclophos Conditioning | 02 | N | 220034440 | DOXORUBICIN |
| 220019856 | 220009148 | 1.8 | 78.3 | Curative (C) | 2016-07-31 | 2016-08-09 | CAV | N | N | 220034447 | FIGARO TRIAL |
| 220019858 | 220009153 | 1.7 | 67.3 | Curative (C) | 2017-04-07 | 2017-04-07 | INTERFERON | 02 | N | 220034482 | INTERFERON |
| 220019859 | 220009160 | 1.75 | 62.8 | Curative (C) | null | 2014-09-12 | TRASTUZUMAB | N | N | 220034495 | CLOFARABINE + CYTSARABINE + IDARUBICIN |
| 220019860 | 220014883 | 1.77 | 78.9 | Palliative (P) | null | 2013-11-19 | Depocyte Intrathecal | N | N | 220034505 | TRASTUZUMAB |
| 220019861 | 220014884 | 1.6 | 53 | Palliative (P) | 2019-07-26 | 2019-07-27 | Fluorouracil + Folinic Acid Weekly | N | null | 220034510 | LIPOSOMAL CYTARABINE |
| 220019862 | 220022218 | 1.75 | 67.3 | Curative (C) | 2014-01-25 | 2014-01-31 | INTERFERON | N | null | 220034521 | CAPECITABINE |
| 220019863 | 220009174 | 1.72 | 51 | Disease modification (D) | 2017-10-11 | 2017-10-22 | DAUNORUBICIN | null | null | 220034531 | CARBOPLATIN |
| 220019864 | 220014887 | 1.78 | null | null | 2017-01-31 | 2017-01-31 | Ipilimumab | N | N | 220034543 | CARBOPLATIN + VINORELBINE |